Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695835 · ClinicalTrials.gov registry record
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
A clinical trial of Adenocarcinoma, sponsored by Gary Onik MD.
- Completed
- Registry status
- 27
- Enrollment target
- 1
- Study location
NCT03695835: Completed study of Adenocarcinoma, sponsored by Gary Onik MD.
NCT03695835 is a study of Adenocarcinoma that has completed, run by Gary Onik MD. The registered enrollment target is 27 participants, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03695835, a study of Adenocarcinoma, has completed, sponsored by Gary Onik MD.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Primary Outcome
Time to death after the start of treatment
Conditions Studied
Interventions
- DEVICE Ablation
- DRUG Immunotherapeutic Agents
Study Locations (1)
Florida
- The Center for High Risk and Recurrent Prostate Cancer - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-04-11 |
| Est. Completion | 2020-06-17 |
What the finished NCT03695835 record still lists
NCT03695835 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 95-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Ablation is the first listed.
NCT03695835 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03695835 about?
NCT03695835 is a clinical study titled "A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.". A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospec...
What is the current status of trial NCT03695835?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2018-04-11. Estimated completion is 2020-06-17.
What conditions does trial NCT03695835 study?
This clinical trial studies the following conditions: Adenocarcinoma.
What interventions are being tested in trial NCT03695835?
The interventions under investigation include: Ablation (DEVICE), Immunotherapeutic Agents (DRUG).
Who is sponsoring clinical trial NCT03695835?
This trial is sponsored by Gary Onik MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03695835 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03695835's enrollment target sits among peer trials
27 21st of 26 higher than 6 of 26 other Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
RECRUITING · Phase 1
-
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
RECRUITING · Phase 1
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI